A NEW DRUG designed to “seek and destroy” common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.
The Phase 1 clinical trial will help determine if EP-100 is safe and effective for use among patients with solid cancer tumours, with fewer side effects than chemotherapy or radiation treatment.
TCRS is a partnership of the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.
The partnership allows molecular and genomic discoveries made by TGen and others around the world to reach the patient bedside in the Virginia G. Piper Cancer Center at Scottsdale Healthcare as quickly as possible through clinical trials with agents directed at specific targets in patients’ tumours.
The TCRS said the drug is a membrane-disrupting peptide (tMDP) designed to “seek and destroy” cancer cells by targeting those with excessive luteinizing hormone releasing hormone (LHRH) receptors.
Excessive LHRH receptors are found in a wide range of cancers, including breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers.
The study is designed to evaluate the safety of EP100 and will enrol as many as 36 adult patients with solid tumours whose tumour biopsies indicate that they have excessive LHRH receptors.
EP-100 will be administered intravenously for three out of four weeks. Once the maximum tolerated dose has been established, additional subjects with specific diagnoses of either breast, ovarian, endometrial, pancreatic or prostate cancer will be enrolled.
EP-100 is produced by Esperance Pharmaceuticals www.esperancepharma.com and was culled from a range of drugs tested at TGen Drug Development Services (TD2) in Scottsdale.
Add a comment